UniProt Q9P289 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Neratinib | 98.7% | 1.3% | 93.18 | 0.597 |
| 2 | Bosutinib | 94.4% | 5.6% | 87.22 | 0.555 |
| 3 | Nintedanib | 86.5% | 13.5% | 90.23 | 0.608 |
| 4 | Midostaurin | 65.0% | 35.0% | 78.64 | 0.500 |
| 5 | Defactinib | 59.4% | 40.6% | 92.68 | 0.450 |
| 6 | Pemigatinib | 49.1% | 50.9% | 98.23 | 0.718 |
| 7 | Darovasertib | 39.6% | 60.4% | 96.99 | 0.719 |
| 8 | Dasatinib | 20.5% | 79.5% | 87.97 | 0.699 |
| 9 | Ceritinib | 18.9% | 81.1% | 95.44 | 0.618 |
| 10 | Capivasertib | 18.4% | 81.6% | 96.48 | 0.644 |
| 11 | Pexidartinib | 15.5% | 84.5% | 99.49 | 0.631 |
| 12 | Fedratinib | 15.1% | 84.9% | 96.21 | 0.576 |
| 13 | Remibrutinib | 13.7% | 86.3% | 99.50 | 0.721 |
| 14 | Quizartinib | 12.6% | 87.4% | 99.50 | 0.737 |
| 15 | Canertinib | 12.1% | 87.9% | 96.49 | 0.671 |
| 16 | Inavolisib | 11.6% | 88.4% | 100.00 | 0.679 |
| 17 | Repotrectinib | 9.6% | 90.4% | 84.21 | 0.608 |
| 18 | Entrectinib | 9.4% | 90.6% | 93.69 | 0.671 |
| 19 | Futibatinib | 9.2% | 90.8% | 98.48 | 0.718 |
| 20 | Dacomitinib | 8.6% | 91.4% | 97.99 | 0.664 |
Paralog block
MST1_STK4, MST2_STK3, MST3_STK24, MST4
EMT expression
Not in the EMT expression panel.
High-confidence drugs
- Neratinib — inh 98.7% · KISS 39.95
- Bosutinib — inh 94.4% · KISS 29.32
- Nintedanib — inh 86.5% · KISS 22.88
Selectivity landscape vs inhibition on MST4
Each point is one of the 92 approved drugs; color = inhibition % on MST4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…